MX2023007610A - Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno. - Google Patents

Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno.

Info

Publication number
MX2023007610A
MX2023007610A MX2023007610A MX2023007610A MX2023007610A MX 2023007610 A MX2023007610 A MX 2023007610A MX 2023007610 A MX2023007610 A MX 2023007610A MX 2023007610 A MX2023007610 A MX 2023007610A MX 2023007610 A MX2023007610 A MX 2023007610A
Authority
MX
Mexico
Prior art keywords
antigen
momp
targeting
presenting cells
vaccine based
Prior art date
Application number
MX2023007610A
Other languages
English (en)
Inventor
Yves Levy
Gérard Zurawski
Sandra Zurawski
Sylvain Cardinaud
Mireille Centlivre
Lydie Dieudonne
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2023007610A publication Critical patent/MX2023007610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Las clamidias son patógenos bacterianos intracelulares responsables de una variedad de infecciones; los inventores produjeron un anticuerpo que se dirige contra un antígeno de superficie (es decir, CD40) de una célula presentadora de antígeno (es decir, una célula dendrítica) en el que la cadena pesada y/o la cadena ligera se conjugan con el dominio MOMP VS4 de Chlamydia trachomatis para su uso como vacuna.
MX2023007610A 2020-12-23 2021-12-22 Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno. MX2023007610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20306668 2020-12-23
PCT/EP2021/087211 WO2022136508A1 (en) 2020-12-23 2021-12-22 Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells

Publications (1)

Publication Number Publication Date
MX2023007610A true MX2023007610A (es) 2023-07-12

Family

ID=74191500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007610A MX2023007610A (es) 2020-12-23 2021-12-22 Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno.

Country Status (7)

Country Link
EP (1) EP4267176A1 (es)
JP (1) JP2024500237A (es)
KR (1) KR20230124672A (es)
CN (1) CN116940373A (es)
CA (1) CA3205280A1 (es)
MX (1) MX2023007610A (es)
WO (1) WO2022136508A1 (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DK2114985T3 (en) 2007-02-02 2015-03-30 Baylor Res Inst Complexes of multivariable antigens and target antibody, a humanized
WO2010104747A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
EP2966091B1 (en) 2008-07-16 2018-04-25 Baylor Research Institute Agonistic anti-cd40 antibodies
JP2013504599A (ja) 2009-09-14 2013-02-07 ベイラー リサーチ インスティテュート ランゲルハンス細胞に向けられたワクチン
WO2012021834A1 (en) 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
EP2635310A2 (en) 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2014085580A1 (en) * 2012-11-28 2014-06-05 Baylor Research Institute Methods and compositions involving a flu vaccine
RS60135B1 (sr) * 2013-03-18 2020-05-29 Statens Seruminstitut Vakcine protiv hlamidije sp.
JP7037884B2 (ja) * 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
JP7038064B2 (ja) * 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用

Also Published As

Publication number Publication date
CN116940373A (zh) 2023-10-24
EP4267176A1 (en) 2023-11-01
WO2022136508A1 (en) 2022-06-30
CA3205280A1 (en) 2022-06-30
KR20230124672A (ko) 2023-08-25
JP2024500237A (ja) 2024-01-05

Similar Documents

Publication Publication Date Title
CO2019010273A2 (es) Productos microbianos y usos de los mismos para mejorar la recuperación de petróleo
TW200744632A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
CR20200461A (es) Método para tratar las enfermedades asociadas al vph
BR112018074415A2 (pt) composição inoculante não aquosa sólida, semente de planta revestida, kit, e, método.
Huws et al. Interactions of some common pathogenic bacteria with Acanthamoeba polyphaga
MX2019013142A (es) Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
BRPI0514982A (pt) adjuvante de glicosilceramida para antìgenos de sacarìdeo
DOP2012000307A (es) Composiciones solidas
WO2008097866A3 (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
CU20190076A7 (es) Combinación fungicida sdhi
MX340017B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2020035741A3 (en) Antibodies against disease causing agents of poultry and uses thereof
WO2006095330A3 (en) Methods and immunogenic cell preparations for treating antigen-associated diseases
EP1455817A4 (en) EXOPOLYSACCHARIDE OF GOLD STAPHYLOCOCCUS AND PROCESS
BR112013025049A2 (pt) máquina de mercadorias
BR112019024738A2 (pt) Uso de um ou mais óleos vegetais metilados, composição inoculante líquida, semente de planta revestida, kit, e, método
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
AR063026A1 (es) Anticuerpos dirigidos contra ccr5 y la utilizacion de los mismos
AR066318A1 (es) Cerradura de puerta
MX2021014236A (es) Anticuerpos contra agentes patogenos de las aves de corral y usos de estos.
MX2022007775A (es) Composición para usarse en terapia de microbiota.
MX2023007610A (es) Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno.
EA200701766A1 (ru) Антитела против антигенов candida
EA202190876A1 (ru) Композиции, содержащие бактериальные штаммы